Why Is Cara Therapeutics (CARA) Stock Down 27% Today?

This data comes from the company's Part A KOURAGE-1 study. It's designed to determine the dose that will be used for the drug during later parts of the clinical trial. The bad news here is that none of the doses that were tested showed meaningful clinical benefit over placebo. What This Means for CARA Stock CARA stock is down 26.7% as of Thursday morning. That builds on a year-to-date drop of 10.6% when markets closed yesterday. More Stock Market News for Thursday On the date of publication, William White d ...